The latest learning and CPD content on anticoagulation. Under ‘Other resources’ you will find all our other content related to anticoagulation.
Pharmacists should note the National Institute for Health and Care Excellence’s updated guidance on use of pharmacological thromboprophylaxis in a range of hospitalised patient groups.
Clarithromycin linked to increased haemorrhage risk in patients treated with direct oral anticoagulantsSubscription
Older adults taking direct oral anticoagulants are more likely to be admitted to hospital for haemorrhage after receiving clarithromycin compared with azithromycin, a study published in JAMA Internal Medicine has suggested.
Lower gastrointestinal bleeding in patients with atrial fibrillation who are being treated with oral anticoagulants is associated with a higher risk of being diagnosed with colorectal cancer, a study published in the European Heart Journal suggests.
Apixaban is associated with less major bleeding, death and hospitalisation than warfarin, regardless of a patient’s stroke history, a secondary analysis of the AUGUSTUS trial has indicated.
Combinations of drugs involving anticoagulants are one of the most frequent causes of medicine-related hospital admissions, but pharmacists can help reduce the risk.
Compared with patients taking warfarin monotherapy, those taking aspirin and warfarin were at a higher risk of a bleeding event but the rate of thrombotic events was similar.
People with atrial fibrillation who have dementia are less likely to receive oral anticoagulants (OACs) than those without cognitive impairment, research has shown.
Direct oral anticoagulants carry lower risk of major bleeding versus warfarin, data showSubscription
Research from primary care suggests apixaban may be the safest of the direct oral anticoagulants overall.
Results from an ongoing trial of 228 patients with acute major bleeding show that patients taking andexanet experienced a reduction in anti-FXa activity.
Adults with non-valvular atrial fibrillation prescribed apixaban have a lower rate of ischaemic stroke and systemic blood clots compared with those prescribed rivaroxaban, according to a retrospective cohort study in Annals of Internal Medicine.
Patients with atrial fibrillation report several negative experiences associated with changes to their anticoagulation therapy — something that shared decision-making and patient education could help to address, research has suggested.